Company intelligence / Profile preview

Labrys Fund

San Mateo, California, United States

Ownership: Private
Development stage: Other

Overview

Labrys Biologics was a venture-financed biotech company focused on developing RN-307, an anti-CGRP monoclonal antibody for chronic migraine. The candidate successfully completed Phase 1 trials (n=74+) and was poised to enter Phase 2 at the time of acquisition. Labrys was acquired by Teva in 2014, with its lead asset ultimately leading to the migraine prevention drug fremanezumab (Ajovy), now approved and marketed by Teva[1][2][4].

Therapeutic areas: Neurology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Pfizer (acquisition of RN-307 asset)

Beyond the preview

Go deeper on Labrys Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Labrys Fund.

Explore the full profile